COMPANY PROFILE

OncoLens

Explore full profile

Driving Timely, Precise Cancer Care

Atlanta, United StatesFounded 2016Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About OncoLens

OncoLens' mission is to ensure every cancer patient receives the right treatment at the right time. Utilizing a portfolio of solutions including AI driven informatics, data integration and care team collaboration tools, the platform enables providers to make the best decision possible for the patient.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Atlanta, United States
Employees: 35
Open positions: None listed
Dealroom signal: 84.8/100
Industry: Health
Sub-industry: Pharmaceutical, Health Platform
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: SaaS
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Oct 2024	$16M	$64M	Martin Ventures · Cross-Border Impact Ventures · SeedToB Capital · BIP Capital	↗
EARLY VC✓Equity / VC	Jul 2023	$0	—	Cross-Border Impact Ventures	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

OncoLens website traffic

Latest recorded traffic for OncoLens is 8.8K monthly website visits, up 51.7% over the last three months. OncoLens's team grew 29.6% over the past year.

Latest monthly visits8.8K 3-month web change+51.7% 1-year team growth+29.6%

Monthly website visitsMay 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HEHEPHAISTOS-PharmaDeveloping Tomorrow’s immuno-oncology and modulator therapy \| A single platform for defeating cancer and much more	Orsay, France	Operational	19	$9.6M	$20M
CGCold GenesysOncolytic immunotherapy \| CG0070 \| Cold Genesys	Santa Ana, United States	Operational
MPMaaT PharmaDevelops a series of microbiome-based drugs targeting mortality and comorbidities associated with blood cancer treatments	Lyon, France	Operational
MTMonopar TherapeuticsEmerging biopharmaceutical company focused on developing orphan oncology compounds	Lake Forest, United States	Operational
DPDeciphera PharmaceuticalsA clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies	Waltham, United States	Acquired
CACantargiaDevelops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells	Lund Municipality, Sweden	Operational
INInformedDNAExpert genetic counseling services via telephone to help individuals develop a personalized healthcare plan	Saint Petersburg, United States	Operational
NTNEOGAP TherapeuticsImagine if cancer patients who lack efficient treatment options could be cured	Stockholms kommun, Sweden	Operational